会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Method for immobilizing ligand or compound having ligand bonded thereto
    • 固定具有配体键合的配体或化合物的方法
    • US5866387A
    • 1999-02-02
    • US894782
    • 1997-08-28
    • Eiji OginoKazuo SuzukiNobutaka Tani
    • Eiji OginoKazuo SuzukiNobutaka Tani
    • B01J20/32C12N11/04C12N11/06C12N11/08G01N33/544
    • B01J20/3274B01J20/3204B01J20/321B01J20/3212B01J20/3251B01J20/3255Y10S530/814Y10S530/815Y10S530/816
    • There is provided a method for immobilizing a ligand by reacting a solvent-insoluble carrier having aldehyde group with a compound shown by the general formula: ##STR1## wherein X is --S-- or --O--, R.sup.1, R.sup.2 and R.sup.6 are the same or different, each of which is hydrogen atom or an alkyl group having 1 to 4 carbon atoms, R.sup.3 is hydrogen atom or a substituent wherein an atom adjacent to nitrogen atom shown in the above-mentioned general formula has no unsaturated bond, R.sup.4, R.sup.5 and R.sup.7 are arbitrary substituents; provided that only one partial chemical structure of HX--C--C--NHR.sup.3 wherein X and R.sup.3 are the same as defined above or HX--C--C--C--NHR.sup.3 wherein X and R.sup.3 are the same as defined above is contained in one compound described above by which, a ligand or a compound to which a ligand is bonded can react specifically and effectively with aldehyde group in a solvent-insoluble carrier at a prescribed position to form a stable bond.
    • PCT No.PCT / JP96 / 00450 Sec。 371日期1997年8月28日 102(e)日期1997年8月28日PCT 1996年2月26日PCT公布。 第WO96 / 26786号公报 日期1996年6月9日提供了通过使具有醛基的溶剂不溶性载体与通式如下的化合物反应来固定配体的方法:其中X是-S-或-O-,R 1,R 2 R6相同或不同,分别为氢原子或碳原子数1〜4的烷基,R3为氢原子或上述通式所示的与氮原子相邻的原子没有不饱和基团的取代基 键,R4,R5和R7是任意的取代基; 只要其中X和R 3与上述定义相同的HX-CC-NHR3的仅一部分化学结构或其中X和R 3与上述相同的HX-CCC-NHR 3包含在上述一种化合物中,其中a 配体或配体所结合的化合物可以在规定的位置上与溶剂不溶性载体中的醛基特异性和有效地反应以形成稳定的键。
    • 9. 发明授权
    • Process for adsorbing and removing tumor necrosis factor-.alpha.
    • 吸附和去除肿瘤坏死因子-α的方法
    • US06127528A
    • 2000-10-03
    • US283964
    • 1999-04-02
    • Fumiyasu HiraiNobutaka TaniTakashi Asahi
    • Fumiyasu HiraiNobutaka TaniTakashi Asahi
    • C07K14/525C07K1/22A61K38/19C07K1/14C07K14/00
    • C07K14/525Y10S930/144
    • The present invention relates to an adsorbent being capable of efficiently removing tumor necrosis factor-.alpha. (TNF-.alpha.) in a body fluid, an adsorber using the adsorbent and a process for adsorbing and removing TNF-.alpha., namely an adsorbent of TNF-.alpha., wherein onto a water-insoluble carrier a compound having a functional group represented by the formula (I): ##STR1## wherein X.sup.- is an anionic functional group, A is a substituent group except for the anionic functional group, n is an integer of 0 to 4 and in case n is at least 2, groups A, the number of which is n, may be the same or different from each other; a process for adsorbing and removing TNF-.alpha., which comprises coming the adsorbent into contact with a body fluid; and an adsorber for adsorbing TNF-.alpha. wherein a vessel having an inlet and an outlet for a body fluid and being equipped with a means for preventing the adsorbent from flowing to the outside of the vessel, is charged with the adsorbent.
    • 本发明涉及能够有效地去除体液中的肿瘤坏死因子-α(TNF-α)的吸附剂,使用吸附剂的吸附剂和吸附和去除TNF-α的方法,即TNF-α的吸附剂 其特征在于,在水不溶性载体上具有由式(I)表示的官能团的化合物:其中,X为阴离子官能团,A为阴离子官能团以外的取代基,n为0〜 4,在n至少为2的情况下,其数目为n的基团A可以相同或不同; 一种吸附和去除TNF-α的方法,其包括使吸附剂与体液接触; 和用于吸附TNF-α的吸附器,其中具有用于体液的入口和出口的容器并且装备有用于防止吸附剂流向容器外部的装置的吸附器装入吸附剂。
    • 10. 发明申请
    • MODIFIED ERYTHROPOIETIN TO WHICH WATER-SOLUBLE LONG-CHAIN MOLECULE IS ADDED
    • 添加了可溶性长链分子的改良的红细胞膜蛋白
    • US20120264687A1
    • 2012-10-18
    • US13395534
    • 2010-09-15
    • Nobutaka TaniToshihide FujiiHiroyuki WatanabeHirofumi Maeda
    • Nobutaka TaniToshihide FujiiHiroyuki WatanabeHirofumi Maeda
    • A61K38/18A61P7/06
    • A61K9/0019A61K38/1816A61K47/60
    • An object of the invention is to provide a pharmaceutical composition that contains erythropoietin as the active ingredient and has, when administered in humans and/or animals, a hematopoietic effect that lasts for not less than seven days. The invention provides a pharmaceutical composition containing, in an amount equal to not less than 50% of the total erythropoietin, erythropoietin to which two or more water-soluble long-chain molecules are added. The invention also provides a pharmaceutical composition containing erythropoietin to which a water-soluble long-chain molecule is added, wherein the water-soluble long-chain molecule has a molecular weight of not less than 30 kDa. The invention further provides a pharmaceutical composition containing erythropoietin to which a water-soluble long-chain molecule is added, wherein the water-soluble long-chain molecule has a branched chain.
    • 本发明的目的是提供一种含有促红细胞生成素作为活性成分并且在人和/或动物中施用时持续不少于7天的造血作用的药物组合物。 本发明提供一种药物组合物,其含量等于不少于总促红细胞生成素的50%,红细胞生成素,其中加入了两种或更多种水溶性长链分子。 本发明还提供含有促红细胞生成素的药物组合物,其中加入水溶性长链分子,其中水溶性长链分子的分子量不小于30kDa。 本发明还提供含有促红细胞生成素的药物组合物,其中加入水溶性长链分子,其中所述水溶性长链分子具有支链。